News

Back
September 12, 2019

Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month

Salarius’ lead program, Seclidemstat, is in a Phase 1 clinical trial for Ewing sarcoma, a rare and devastating pediatric bone and soft-tissue cancer; Early cohort data expected in 2020

Houston, TX, September 12, 2019Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, announced its support for Childhood Cancer Awareness Month, designated as the month of September. Recognizing the work underway by the National Pediatric Cancer Foundation and the many other organizations, foundations and associations around the world to raise awareness of childhood cancers, Salarius joins with these groups in exploring targeted treatments for children and their families seeking new therapeutic options.

Contact

Jeremy Feffer LifeSci Advisors, Managing Director jeremy@lifesciadvisors.com
Download PDF